[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"persistant-atrial-fibrillation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:persistant-atrial-fibrillation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,77,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100607327","a-global-study-comparing-pulsed-field-ablation-with-electrographic-flow-mapping-versus-posterior-wall-ablation-for-persistent-atrial-fibrillation-100607327",false,"NCT07187115","A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation","A Global Randomized Trial Comparing Pulsed Field Ablation of Pulmonary Veins Plus Extra-PV Sources Utilizing Electrographic Flow Mapping Versus Pulmonary Veins Plus Posterior Wall in Persistent Atrial Fibrillation Patients.","OPTIMIZE","Inclusion Criteria:\n\n1. ≥ 18 years of age, or older if required by local law\n2. Have symptomatic drug-refractory1, persistent AF2, confirmed by both:\n\n   * Documentation, such as physician note, of persistent continuous AF for \\> 7 days and ≤ 365 days and the arrhythmia symptoms\n   * Documentation, within 180 days of enrollment date of either:\n\n     * A 24-hour continuous ECG recording confirming continuous AF or\n     * Two (2) ECGs (from any regulatory cleared rhythm monitoring device) showing continuous AF taken at least 7 days apart\n3. Willing and capable of providing informed consent\n4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center\n5. Willing to receive LUX-Dx™ insertable cardiac monitor (ICM) during the study or already has a LUX-Dx™ ICM that was inserted ≤ 6 months (i.e., within 180 days) of consent, and willing to comply to the LUX-Dx Latitude Clarity transmission instructions\n\nExclusion Criteria:\n\n1. Any of the following atrial conditions:\n\n   1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if1 LA diameter not available, non-indexed volume \\>100 ml (physician note or imaging)\n   2. Any prior left atrial ablation\n   3. Any prior atrial surgery\n   4. Current atrial myxoma\n   5. Current left atrial thrombus\n   6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)\n2. Any of the following cardiovascular conditions:\n\n   1. History of sustained ventricular tachycardia or any ventricular fibrillation\n   2. Severe right ventricular dysfunction with documented echocardiography and\u002For hemodynamic data, per Investigator's discretion\n   3. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible \u002F non-cardiac causes\n   4. Cardiac devices and implants:\n\n      * Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices\n      * Implantable loop recorder, other than LUX-Dx\n      * Interatrial baffle, patent foramen ovale or atrial septal defect closure device or patch\n      * Any left atrial appendage closure or occlusion device\n   5. Presence of any of the following valvular conditions:\n\n      * Any prosthetic heart valve, stenotic valves, ring or repair\n      * Moderate to severe mitral valve stenosis\n      * More than moderate mitral regurgitation\n   6. Hypertrophic or amyloid cardiomyopathy\n   7. Any IVC filter, known inability to obtain vascular access or other contraindication to femoral access\n   8. Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months\n   9. Severe right ventricular dysfunction with documented echocardiography and\u002For hemodynamic data.\n3. Any of the following conditions at Baseline:\n\n   1. Heart failure associated with NYHA Class III or IV\n   2. Most recent documented LVEF \\\u003C 40% within the previous 12 months\n   3. Body Mass Index (BMI) \\> 45.0\n   4. Known coagulopathy or bleeding disorder\n   5. Contraindication to, or unwillingness to use systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation\n   6. Women who are confirmed to be pregnant or lactating at the time of the ablation procedure\n   7. Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen\n   8. Active malignancy (other than squamous cell carcinoma)\n   9. Clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration\n   10. Known active systemic infection\n   11. Untreated diagnosed obstructive sleep apnea with apnea hypopnea index classification of severe (\\>30 pauses per hour) as per the guidelines\n   12. Predicted life expectancy less than one year per investigator medical judgement\n   13. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility\n   14. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure\n   15. Uncontrolled hypertension (SBP \\> 160 mmHg or DBP \\> 95 mmHg on two (2) BP measurements at baseline assessment not attributable to white coat syndrome per Investigator opinion\n   16. CHA2DS2-VASc score ≥ 5\n   17. Known allergic drug reaction to nitroglycerin (excluding hypotension)\n   18. Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted LUX-Dx ICM device\n4. Any of the following congenital conditions:\n\n   1. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality\n   2. History of known congenital methemoglobinemia\n   3. History of known G6PD deficiency\n5. Any of the following conditions in the medical history:\n\n   1. Solid organ or hematologic transplant, or currently being evaluated for a transplant\n   2. Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis\n   3. Any documented history of Prinzmetal Angina or severe non-revascularizable coronary disease\n   4. Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL \u002F min \u002F 1.73 m2, or with any history of renal dialysis or renal transplant\n   5. Any other general health condition that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.\n6. Any of the following events less than or equal to 90 days of the consent date:\n\n   1. Myocardial infarction (MI), unstable angina or coronary intervention\n   2. Any cardiac surgery\n   3. Heart failure hospitalization\n   4. Pericarditis or symptomatic pericardial effusion\n   5. Gastrointestinal bleeding\n   6. Stroke, TIA, or intracranial bleeding\n   7. Any active non-neurologic thrombus and\u002For thromboembolic event\n   8. Carotid stenting or endarterectomy\n   9. Uncontrolled diabetes mellitus or a recorded HbA1c \\> 8.0%","ALL","18 Years",{"count":20,"type":21},699,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA of Pulmonary Veins and LA Posterior Wall (PVI+ PWA) in the treatment of de novo symptomatic drug-refractory persistent atrial fibrillation (PersAF).",[27,28],"Atrial Fibrillation (AF)","Persistant Atrial Fibrillation",[30,31,32],"FARAPULSE","FARAPOINT","OptiMap","RECRUITING","2026-06-29",{"date":36,"type":37},"2026-06-30","ACTUAL",{"date":39,"type":37},"2025-11-07",{"date":41,"type":21},"2030-12",{"name":43,"class":44},"Boston Scientific Corporation","INDUSTRY",42,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100576374","coherent-sine-burst-electroporation-cse-ablation-system-us-ide-study-for-patients-with-atrial-fibrillation-100576374","NCT06784466","Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation","Coherent Sine Burst Electroporation (CSE) Ablation System US Investigational Device Exemption (IDE) Study for Patients With Atrial Fibrillation","COHERENT-AF","Inclusion Criteria:\n\n1. Patients between the ages of 18 and 80 years, or older than 18 if required by local law.\n2. Diagnosis of drug refractory, recurrent, paroxysmal or persistent AF:\n\n   a. Symptomatic paroxysmal AF that is less than 7 days in continuous duration, documented by the following: i. Physician documentation of symptomatic recurrent PAF (2 or more episodes) within 6 months prior to enrollment AND ii. At least 1 documented AF episode from any form of rhythm monitoring within 12 months prior to enrollment.\n\n   b. Symptomatic persistent AF that is sustained beyond 7 days and less than 1 year (≥ 7 and ≤ 365 days), documented by the following: i. Physician documentation of at least 1 symptomatic persistent AF episode within 6 months prior to enrollment.\n\n   ii. Either a 24-hour continuous ECG recording documenting continuous AF OR 2 ECGs from any regulatory cleared rhythm monitoring device showing continuous AF taken at least 7 days apart, within 6 months prior to enrollment.\n3. Effectiveness failure of, intolerance to, or a specific contraindication to at least one Class I or III anti-arrhythmic drug.\n4. Willing and able to give informed consent.\n5. Willingness, ability, and commitment to participate in baseline, follow-up, and rhythm monitoring evaluations for the full length of the study.\n6. Life expectancy \\>1 year.\n\nExclusion Criteria:\n\n1. In the opinion of the Investigator, any known contraindication to an AF ablation (including present left atrial \\[LA\\] thrombus), trans-esophageal echocardiogram (TEE) or computed tomography (CT) scan, or anticoagulation.\n2. Any duration of continuous AF lasting longer than 12 months.\n3. History of any previous left atrial ablation or surgical procedure, including prior left atrial appendage closure.\n4. AF secondary to electrolyte imbalance, thyroid disease, alcohol, or any other reversible or non-cardiac cause.\n5. Left ventricular ejection fraction (LVEF) \\\u003C 35% within 6 months of enrollment (e.g. transthoracic echocardiogram (TTE), multiple-gated acquisition (MUGA), magnetic resonance imaging (MRI), nuclear stress test).\n6. New York Heart Association (NYHA) Class III or IV.\n7. Left atrial diameter \\> 5.0 cm (anteroposterior) within 6 months of enrollment (MRI, CT, TTE, TEE, or physician's note) or non-indexed volume \\>100mL if left atrial diameter is not available.\n8. Current or anticipated implant of a permanent pacemaker, implantable cardioverter or resynchronization device, interatrial baffle, foramen ovale occluder, LA appendage closure, or active implantable\u002Finsertable cardiac loop recorder\u002Fmonitor at the time of the ablation procedure.\n9. Body mass index (BMI) \\>40.\n10. Patients who have not been on anticoagulation therapy for at least 3 weeks prior to the Index Procedure.\n11. Previous cardiac surgery, myocardial infarction, percutaneous coronary intervention or angioplasty (PCI\u002FPTCA) or coronary artery stenting within 3 months prior to enrollment.\n12. Symptomatic valvular disease, history of cardiac valve surgery, or prosthetic mitral and tricuspid valve(s).\n13. Presence of pulmonary vein abnormalities of stenosis or stenting.\n14. Primary pulmonary hypertension.\n15. Uncontrolled or untreated hypertension (two measurements of \\>180mmHg systolic or \\>110 mmHg diastolic at baseline).\n16. Pre-existing hemi-diaphragmatic paralysis.\n17. Renal insufficiency with an estimated glomerular filtration rate (eGFR) \\\u003C 40 mL\u002Fmin\u002F1.73 m2, or any history of renal dialysis or renal transplant.\n18. Rheumatic heart disease.\n19. Unstable angina or ongoing myocardial ischemia.\n20. Hypertrophic cardiomyopathy, advanced restrictive cardiomyopathy, or severe left ventricular hypertrophy (left ventricular thickness \\>15mm).\n21. History of blood clotting or bleeding disease (e.g., thrombocytosis).\n22. History of documented cerebral infarction, transient ischemic attack, or systemic embolism within 6 months prior to enrollment.\n23. Active systemic infection.\n24. Active malignancy or history of treated malignancy within 12 months of enrollment (other than cutaneous basal cell or squamous cell carcinoma, or non-metastatic prostate or breast cancer with life expectancy remaining \\>1 year).\n25. Pregnant or lactating (current or anticipated during study follow-up).\n26. Current enrollment in any other clinical study where testing or results from that study may interfere with the procedure or outcomes measurement for this study.\n27. Any other condition that, in the judgment of the Investigator, makes the patient:\n\n    1. Unlikely to benefit from an AF ablation procedure (e.g., advanced infiltrative cardiomyopathies, severe mitral stenosis or regurgitation, and\u002For cor pulmonale, etc.), or\n    2. A poor candidate for the study (e.g., vulnerable patient population, mental illness, addictive disease, terminal illness, and extensive travel away from the research center).","80 Years",{"count":56,"type":21},360,[24],"To evaluate the safety and effectiveness of the Argá Medtech CSE Ablation System in the treatment of atrial fibrillation.",[27,28,60],"Paroxysmal AF",[62,63,64,65,66],"atrial fibrillation","ablation","coherent sine-burst","electroporation","pulsed field ablation","2026-06-04",{"date":69,"type":37},"2026-06-05",{"date":71,"type":37},"2025-09-10",{"date":73,"type":21},"2027-08",{"name":75,"class":44},"Arga Medtech SA",27,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":4},"100631350","the-effect-of-pulse-field-ablation-of-atrial-fibrillation-involving-posterior-wall-ablation-on-atrial-mechancis-assessed-by-cardiac-magnetic-resonance-imaging-100631350","NCT07499531","The Effect of Pulse Field Ablation of Atrial Fibrillation Involving Posterior Wall Ablation on Atrial Mechancis Assessed by Cardiac Magnetic Resonance Imaging","PF-MRI+","Inclusion Criteria:\n\n* Patient age ≥ 18\n* Established diagnosis of persistent or paroxysmal atrial fibrillation with a I\u002FIIa\u002FIIb indication for catheter ablation (ESC 2020 guidelines)\n* AF ablation procedure planned using pulsed-field ablation and including at least pulmonary vein isolation and posterior wall isolation\n* Episode of AF documented by ECG within the last 12 months\n* Patient able to give written informed consent\n* If female of childbearing potential, have a negative serum pregnancy test and using effective contraception\n* Be affiliated with a French social security system or entitled\n\nExclusion Criteria:\n\n* Only pulmonary vein isolation is scheduled\n* Atrial fibrillation present at ECG during the pre-ablation (V1a) visit\n* Contraindication to oral anticoagulation\n* Intracardiac thrombus\n* Previous ablation in the left atrium\n* Previous heart surgery\n* Significant valvular heart disease defined as any moderate (grade 3) or severe (grade 4) mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis, tricuspid regurgitation, or tricuspid stenosis\n* Contraindication to perform MRI or using the DOTAREM™ contrast product (pacemaker, defibrillator, foreign body or prosthesis, old generation heart valves, old generation ferromagnetic vascular surgical clips, percutaneous devices for endocranial aneurysms, neurosimulator, cochlear implants, automated injection device such as insulin pump, and more generally any non-removable electronic device, severe kidney disease with GFR \\\u003C 30 mL\u002Fmin, documented hypersensitivity to gadoteric acid or to excipients, severe claustrophobia)\n* Patient on AME (state medical aid)\n* Pregnant or breast-feeding female\n* Patient protected by law (guardianship, tutelage measure, deprived of liberty)\n* Participation in another interventional study or being in the exclusion period at the end of a previous study.",{"count":85,"type":21},39,[24],"Assessing the impact of a new atrial fibrillation (AF) catheter ablation energy on left atrial structure and function is of crucial importance.\n\nThe goal of this clinical trial is to assess the effect of pulsed-field ablation of atrial fibrillation on left atrial structure.",[28,60],[90],"Catheter Ablation","NOT_YET_RECRUITING","2026-03-24",{"date":94,"type":37},"2026-03-30",{"date":96,"type":21},"2026-04",{"date":96,"type":21},{"name":99,"class":100},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100614586","ablation-with-the-pfa-system-with-a-large-area-focal-catheter-for-the-treatment-of-persistent-atrial-fibrillation-100614586","NCT07281521","Ablation With the PFA System With a Large-Area Focal Catheter for the Treatment of Persistent Atrial Fibrillation","Safety & Effectiveness of the CardioWave Pulsed Field Ablation System With the QuickShot Nav Large-Area Focal Catheter for Ablation of Persistent Atrial Fibrillation","Quick AF","Inclusion Criteria:\n\n1. Diagnosis of recurrent symptomatic paroxysmal AF (PAF) or persistent AF (PerAF) with the following documentation:\n\n   Paroxysmal AF (Phase A participants)\n   1. Physician's note indicating symptoms consistent with recurrent symptomatic PAF AND\n   2. At least one documented episode of AF captured continuously on 12-lead ECG, or for at least 30 seconds on transtelephonic monitor (TTM), Holter monitor, telemetry strip, or similar within 12 months prior to enrollment\n\n   Persistent AF (Phase A, B, and C participants)\n   1. Physician's note indicating symptoms consistent with recurrent symptomatic PerAF AND\n   2. Any 24-hour ECG recording of continuous AF within 12 months prior to enrollment OR\n   3. Two ECGs from any form of rhythm monitoring showing continuous AF taken at least 7 days apart within 12 months prior to enrollment OR\n   4. History of ≥2 direct current cardioversion (DCCV) performed within 12 months prior to enrollment\n2. Failure or intolerance of at least one antiarrhythmic drug (AAD) (Class I - IV) for AF, as evidenced by recurrent symptomatic PerAF or intolerable side effects due to the AAD\n3. Age 18 through 75 years-old on the day of enrollment\n4. Patient is indicated for an ablation procedure according to society guidelines or study site practice\n5. Patient is willing and able to give informed consent and is willing, able, and committed to participate in baseline and follow-up evaluations for the full duration of the study\n\nExclusion Criteria:\n\n1. Long-standing persistent AF (continuous AF sustained \\> 1 year)\n2. AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse, or other reversible\u002Fnon-cardiac causes\n3. Prior cardiac ablation or surgical procedure (including left atrial appendage (LAA) device or occlusion, or valvular cardiac procedure)\n4. Planned LAA closure procedure or implant of a permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator (with or without biventricular pacing function) for any time during study participation\n5. Presence of any permanent pacemaker, biventricular pacemaker, or implantable cardiac defibrillator (with or without biventricular pacing function) that cannot be programmed, per the manufacturer's recommendations, during the ablation procedure\n6. Patient cannot be removed from AADs for reasons other than AF, which includes participants with Wolff-Parkinson-White (WPW) Syndrome and participants with a history of ventricular tachycardia (VT)\n7. Presence of any IVC filters\n8. Presence of an interatrial baffle or patch\n9. Presence of any pulmonary vein stents\n10. Pre-existing pulmonary vein stenosis\n11. Pre-existing hemidiaphragmatic paralysis\n12. Atrial or ventricular septal defect closure\n13. Atrial myxoma\n14. Presence of any mechanical or biologic prosthetic heart valve\n15. Hemodynamically significant valvular disease as determined by the Investigator\n16. History of pericarditis\n17. History of Rheumatic heart disease\n18. History of thromboembolic event within 6 months prior to Index Ablation Procedure or evidence of intracardiac thrombus at time of the Index Ablation Procedure\n19. Any of the following events within 3 months prior to the Index Ablation Procedure:\n\n    * Myocardial infarction\n    * Unstable angina\n    * Percutaneous coronary intervention\n    * Heart surgery including coronary artery bypass grafting\n    * Heart failure hospitalization\n    * Cerebral ischemic event (stroke or transient ischemic attack (TIA))\n    * Clinically significant bleeding requiring surgical intervention\n    * Pericardial effusion\n    * Ventriculotomy or atriotomy\n20. New York Heart Association (NYHA) Class IV congestive heart failure\n21. Documented left ventricular ejection fraction (LVEF) ≤35% measured by acceptable cardiac testing (e.g., TTE, cardiac CT, etc.) within 6 months prior to enrollment\n22. Hypertrophic cardiomyopathy\n23. Primary pulmonary hypertension\n24. Significant or symptomatic hypotension\n25. Thrombocytosis, thrombocytopenia\n26. Contraindication to, or unwillingness to use, systemic anticoagulation\n27. Patient contraindicated for CT or MRI\n28. Sensitivity to contrast media not controlled by premedication\n29. Women known to be pregnant or breastfeeding, or any women of childbearing potential who are not on a reliable form of birth regulation method or abstinence\n30. Patient is participating in any other potentially confounding research\n31. Serious or untreated medical conditions that would prevent participation in the study, interfere with assessment or therapy, or confound data or is interpretation, including but not limited to:\n\n    * Solid organ or hematologic transplant, or currently being evaluated for organ transplant\n    * Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea\n    * Chronic renal insufficiency with eGFR \\\u003C50 mL\u002Fmin\u002F1.73 m2, any history of renal dialysis, or history of renal transplant\n    * Active malignancy or history of treated cancer within 24 months prior to enrollment\n    * History of severe esophageal ulcers, strictures, esophagitis, esophageal structural abnormality, and uncontrolled\u002Funtreated gastroesophageal reflux disease (GERD)\n    * Active systemic infection\n    * Clinically significant psychological condition that, in the Investigator's opinion, would prohibit the participant's ability to meet the protocol requirements\n    * Predicted life expectancy \\\u003C1 year","75 Years",{"count":111,"type":21},200,[24],"The study evaluates the safety and effectiveness of the investigational QuickShot Nav configuration of the CardioWave System for focal catheter ablation of persistent atrial fibrillation (PerAF).",[28],[63,66,62],"2025-12-04",{"date":118,"type":37},"2025-12-15",{"date":120,"type":37},"2023-02-27",{"date":122,"type":21},"2027-06",{"name":124,"class":44},"CardioFocus",3]